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There is currently a lack of an efficient, objective and systemic approach towards the 
classification of Alzheimer’s disease (AD), due to its complex etiology and pathogenesis. As 
AD is inherently dynamic, it is also not clear how the relationships among AD indicators vary 
over time. To address these issues, we propose a hybrid computational approach for AD 
classification and evaluate it on the heterogeneous longitudinal AIBL dataset. Specifically, 
using clinical dementia rating as an index of AD severity, the most important indicators (mini-
mental state examination, logical memory recall, grey matter and cerebrospinal volumes from 
MRI and active voxels from PiB-PET brain scans, ApoE, and age) can be automatically 
identified from parallel data mining algorithms. In this work Bayesian network modelling 
across different time points is used to identify and visualize time-varying relationships among 
the significant features, importantly in an efficient way using only coarse-grained data. 
Crucially, our approach suggests key data features and their appropriate combinations that 
are relevant for AD severity classification with high accuracy. Overall, our study provides 
insights into AD developments and demonstrates potential of our approach in supporting 




Alzheimer’s disease (AD) is a devastating neurodegenerative disorder with currently 
incompletely characterised etiology and no effective treatment. AD and its prodromal stage, 
mild cognitive impairment (MCI), are associated with multiple pathogenesis, markers and 
risks. For example, age is a well-known risk indicator of developing AD	1.	Medical history of 
neurological disorder has also been linked to higher AD risk 2. In terms of biomarkers, 
apolipoprotein E (ApoE) Ɛ4 allele is associated with higher AD risk than the more common 
ApoE Ɛ3 allele 3,4. ApoE Ɛ4 allele has also been linked to two key pathologies: beta amyloid, a 
major component of senile plaque of AD, and the hyperphosphorylation of microtubule-
associated tau protein that leads to neurofibrillary tangles 5,6,7. Brain imaging data such as 
magnetic resonance imaging (MRI) and positron-electron tomography (PET) with [11C]-
Pittsburgh compound B (PiB) or [18F]-fluorodeoxyglucose (FDG) tracers have been shown to 
be reliable methods of diagnosis and prediction of AD progression with accuracy (area under 
receiver operating characteristic curve, AUC 8) being 0.82 and 0.87 in 9,10 respectively. 
Some other studies focusing on brain imaging data were conducted for AD identification, 
such as 11, 12. Within clinical setting, psychological/functional assessments are typically 
conducted, which may include mini-mental state examination (MMSE), logical memory 
immediate/delayed recall assessments (LMIR/LMDR), and clinical dementia rating (CDR) 13.  
Thus, it is clear that the disease can be linked to factors across multiple domains 14. 
Further, our recent work on multimodal kernel approach applied to combined MRI-PET 
neuroimaging data has shown more accurate AD diagnosis and prognosis than each 
individual modality 15. Thus, multimodal data fusion may provide more accurate and holistic 
picture of AD data, better decision support for AD diagnosis and prognosis 16. In addition to 
the aforementioned brain imaging multimodalities, one may also augment with 
psychological/functional assessments, blood tests, ApoE genotype, and medical history. 
However, coming out with systematic and automated analytical approach for such 
heterogeneous AD data is still a largely open problem. Despite extensive studies on AD, 
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most of the studies considered only a limited number of factors, and hence may be 
insufficient to provide a systemic understanding or characterization of this complex disease. 
For example, a novel multiple kernel learning framework combing multimodal features for AD 
classification was proposed in 17, however only imaging data, i.e. cerebrospinal fluid 
biomarkers (CSF) and MRI, were taken into account regarding very limited data size which 
only includes 70 healthy controls and 50 progressive MCI patients. A hybrid model, 
combining features reduction technique by using rough sets and genetic algorithm and 
uncertain reasoning technique based on Bayesian network (BN), was proposed in 18, but 
only psychological/functional assessments were conducted and the obtained BN did not 
show the strength of the corresponding relationships among the assessments, neither the 
evolution of the BNs across time. 
Therefore, it is still not completely known what factors are relatively more important than 
others with respect to AD, and how they can be influenced under certain conditions or stages 
of the disease. With data related to AD becoming more readily available, mathematical and 
computational approaches become necessary to integrate, analyse and visualise large, 
complex and heterogeneous data to provide holistic insights into the disease mechanisms, 
improve diagnosis and risk predictions, and suggest stratified treatments or interventions 19,20. 
However, a systemic computational approach that can rapidly integrate coarse-grained, 
heterogeneous data for AD classification is currently lacking.  
In this work, we apply a combination of complementary data mining and BN modelling 
approaches on a heterogeneous longitudinal dataset to efficiently identify key features from 
coarse-grained data and understand probabilistic dependencies among multiple AD factors 
and their changes over time. In particular, we used the Australian Imaging Biomarkers and 
Lifestyle flagship study of ageing (AIBL) dataset 21, one of the largest, well-characterised, 
longitudinal (4.5 years) studies on healthy ageing and AD. It was collected from baseline and 
then followed up every 18 months. The data used will be coarse-grained: (i) ApoE allele type 
instead of genome sequence data; (ii) total number of active pixels (PET) or total volume 
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(MRI) from brain imaging data instead of brain region specific; (iii) overall scores from 
psychological/functional tests instead of specific questions from a test; and (iv) overall 
neurological history instead of specific neurological disorders. Compared with the 
Alzheimer’s Disease Neuroimaging Initiative (ADNI) data22, the AIBL data provides more PiB-
PET data samples and more allele information of the ApoE genotype. The AIBL data is also 
more heterogeneous, including both imaging and non-imaging data types, than the Open 
Access Series of Imaging Studies (OASIS) which has only imaging data23. Our proposed 
computational framework is summarized in Fig. 1.  
 
Fig. 1. Proposed hybrid computational framework. CAIM: class-attribute interdependence 
maximization. 10-fold CV: 10-fold cross validation. SMOTE: synthetic minority over-sampling 
technique. Correlation analysis validates usage of clinical dementia rating (CDR) as an index of AD 
severity. The CAIM algorithm is used to discretize the considered features with respect to CDR. 
Entropy-based feature selection with 10-fold CV is applied to a model development set to identify 
features most relevant for predicting AD severity. SMOTE technique is implemented to balance 
unbalanced disease classes in the model development set in order to avoid inflated performance 
estimates. 10-fold CV is used to evaluate the capability of various scoring functions of BNs and 
determine the BN with the optimal predictive performance. The trained BN models are evaluated on 
an independent test set partitioned from the original data. Prior knowledge from domain experts is 




Significant correlation between clinical diagnosis and clinical dementia rating 
Clinical dementia rating (CDR) is designed to stage the severity of AD based on the state of 
the participants in terms of memory, orientation, judgment and problem solving, community 
affairs, home and hobbies, and personal care 24. It has been considered as a more objective 
assessment for AD severity due to its gold standard to classify each individual into one of the 
following 5 categories by corresponding CDR scores: normal control (CDR=0), very mild 
(CDR=0.5), mild (CDR=1), moderate (CDR=2), and severe (CDR=3) dementia 24. This is in 
contrast to relatively subjective clinical diagnosis, e.g. 25. Most recently, it has been reported 
that the CDR has been used to identify AD severity 26, 27. Studies in 28 showed that CDR 
suits well to serve as a comprehensive primary outcome measure for a study that will enrol 
subjects with early AD and follow them to more advanced stages. To avoid subjective clinical 
diagnosis, we will use CDR as a measure of severity in this study. To provide evidence to 
support this, we calculate the Pearson’s product-moment correlation between clinical 
diagnosis and CDR. Within the AIBL data, we selected 1473 complete pairs of clinical 
diagnosis and corresponding CDR score without missing value data, and found that CDR is 
highly correlated to diagnosis. Fig. 2 illustrates the data distribution across diagnostic 
categories with respect to different CDR scores. The correlation coefficient (Cor.) with 
respect to diagnosis is 0.81 with 95% confidence interval (CI) of (0.79-0.83) and p < 2.2e-16. 




Fig. 2.	 Strong correlation between clinical diagnosis and Clinical Dementia Rating (CDR) 
categories. Vertical bars: healthy control (HC); horizontal bars: MCI; diagonal brick bars: AD; Cor.: 
correlation coefficient; CI: confidence interval. CDR scores reflect 5 categories: normal controls 
(CDR=0), very mild (CDR=0.5), mild (CDR=1), moderate (CDR=2), and severe (CDR=3) patients. 
Clinical diagnosis contains 3 categories: HC, MCI, and AD. The data distribution along with the Cor., 
95% CI, and p-value have shown significant correlation between clinical diagnosis and CDR. 
Data setup and discretisation 
We considered a total of 33 heterogeneous features: 2 demographics items, 10 medical 
history data, 13 blood test results including ApoE genotype, 4 psychological and functional 
assessments (including CDR), 4 MRI and PiB-PET imaging data (see Supplementary Table 
S1 for the full list of the data features and descriptions). Given the CDR categories, the 
distribution of dementia cases in different stages of disease severity at baseline (BL) and 18 
(M18), 36 (M36), and 54 (M54) months from baseline is shown in Supplementary Table S2. 
The data was arranged into the following 3 groups: (1) 197 participants with complete data at 
BL and 130 participants with complete data occurring at least once within M18-M54; (2) 133 
participants with complete time-evolved data at both BL and at least once within M18-M54; 
and (3) 57 participants with complete time-evolved data across all times. Compared with the 
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first 2 groups, group 3 has much smaller data samples, especially the corresponding CDR of 
this group has only 2 categories (i.e., normal and very mild). As this effect will be significant 
in the study of time evolution of relationships in the data, we shall focus on the first 2 data 
groups (See Group1 and Group 2 in Supplementary Table S2). 
We discretised all features in order to make the subsequent BN robust and prevent over-
fitting during structural learning 29. The data features were discretized with respect to CDR 
categories using class-attribute interdependence maximization (CAIM) algorithm 30 (see 
Methods). The feature values were grouped into specific sets of intervals depending on how 
many categories each feature has. In both Groups 1 and 2, there was no subject with severe 
CDR category. As the number of individuals with moderate CDR category was relatively 
small, the subjects from mild and moderate CDR categories were combined into one 
mild/moderate CDR category. CDR and MMSE were discretised into 3 and 4 intervals, 
respectively, according to their definitions (Supplementary Table S1). ApoE genotypes were 
discretised into 5 categories as there are a total of 5 different combinations of alleles: ε3ε2, 
ε3ε3, ε4ε2, ε4ε3, and ε4ε4. Features without explicit categories were discretised into the 
same number of intervals as that of CDR i.e. 3 intervals. 
Feature selection and data balancing 
For easier interpretation, shorter training time, and to prevent overfitting and reduce noisy 
data, feature selection is needed before data modelling. We concurrently applied entropy-
based information gain, information gain ratio, and symmetrical uncertainty algorithms, in 
order to obtain a consistently significant subset of features. Note that the feature selection 
procedure was applied to the model development set only 31. After 10-fold cross validation 
(10-FCV), the most relevant features were identified including three psychological/functional 
assessments (MMSE, LMIR, and LMDR), neuroimaging features extracted from MRI (grey 
matter volume (GM) and cerebrospinal fluid volume (CSF)) and active voxels from PiB-PET, 
ApoE genotype, and age. In total, 8 out of 32 most important and stable features with respect 
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to CDR were selected for model training. All selected features had selection frequency of 
100%. To further validate our feature selection results, we carried out the correlation analysis 
between CDR and the selected features. Pearson’s and Spearman’s correlation filtering 
showed that three considered psychological/functional assessments were the most 
significant features with respect to CDR, followed by three neuroimaging features, ApoE and 
age. This observation was consistent with the outputs of the three implemented entropy-
based feature selection algorithms. The rankings of the features with respect to the CDR 
category obtained for each fold are shown in Supplementary Figures S5 - S14. 
Probabilistic dependencies among key features 
A total of 589 subjects with a complete data set of GM, CSF, PiB-PET, ApoE genotype, age 
and cognitive/ functional assessments collected over the period of 4.5 years was used for BN 
modelling. Prior to learning, domain knowledge was identified to aid the BN structure learning 
process (see Methods section for more details). The optimized BN structure via 10-fold CV 
(with AUC of 0.82) is shown in Fig. 3. Here, each rectangle corresponds to a domain variable 
while arrows denote probabilistic dependencies between associated variables. Thicker 
arrows reflect stronger influences between variables (determined by the p-value of the 
corresponding influence). Example of realizations of BN structures extracted from different 
folds during the cross validation procedure are shown in Supplementary Figure S15. The 
BNs in Supplementary Figure S15 look generally similar to the BN in Fig. 3, with most of the 
variations coming from the weaker (less probable) connections.  
Fig. 3 shows that for the predisposing factors, CDR is directly influenced by CSF, 
followed by GM and PiB-PET, while age and ApoE indirectly influence CDR via GM, PiB-PET, 
and CSF. The probabilistic influences from PiB-PET to GM and CSF, and that from GM to 
CSF are also discovered by the BN. In terms of psychological/functional assessments, the 
BN reveals that the probabilistic influences between CDR and psychological/functional 
assessments are much stronger than those between predisposing indicators/biomarkers and 
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CDR. CDR is most strongly linked to MMSE, followed by LMDR, then LMIR. The BN also 
shows the directly probabilistic dependency from LMDR to LMIR. The BN model constructed 
using predisposing indicators/biomarkers and their direct/indirect influences on the CDR 
score achieved the multi-class classification accuracy (MCA) of 0.72, 95%CI [0.59, 0.83] and 




Fig. 3. Optimized Bayesian network (BN) structure via 10-fold CV with probabilistic 
dependencies among predisposing factors, psychological/functional assessments, and AD 
severity. ApoE: apolipoprotein E genotype; GM: grey matter volume; CSF: cerebrospinal volume; PiB-
PET: Pittsburgh compound B - positron-electron tomography; CDR: clinical dementia rating; MMSE: 
mini-mental state examination; LMIR/LMDR: logical memory immediately/delayed recall. BN is 
constructed based on the complete data. The thickness of the arrows represents the strength of the 
probabilistic influence between features. CDR is directly influenced by neuroimaging-based CSF, GM, 
and PiB-PET, while indirectly influenced by age and ApoE. The probabilistic influences between CDR 
and psychological/functional assessments are much stronger than those between predisposing 
indicators/biomarkers and CDR. 
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Dynamic changes of probabilistic dependencies in network structure 
Taking advantage of the available longitudinal dataset, we constructed BNs across 2 
different time points (BL and at least once at a later time during the M18-54 time interval) for 
two groups of participants. Group 1 consisted of 197 subjects at BL and 130 subjects 
assessed at least once within the M18-M54 time interval (referred to as ‘Later time’). Group 2 
included the same 133 participants at both BL and the ‘Later time’. Figs. 4 shows BNs 
constructed for Group 1 at BL (Fig. 4A), Group 1 at M18-54 (Fig. 4B), Group 2 at BL (Fig. 
4C), Group 2 at M18-54 (Fig. 4D).  
Given Group 1, the obtained BN at BL showed a sensitivity of 0.82 and specificity of 0.60 
for healthy control, a sensitivity of 0.41 and specificity of 0.78 for very mild AD, a sensitivity of 
0.33 and specificity of 0.96 for mild/moderate AD (Supplementary Table S3). The MCA and 
AUC for the BN model based on the Group 1 data was 0.67 and 0.80 respectively.  
As the distributions of CDR categories at a later time are different from those at BL, 
some probabilistic dependencies at a later time may differ from those at BL. In particular, 
there are 6% (12/197) mild/moderate AD patients at BL compared to 12% (15/130) at a later 
time. Compared to the BN at BL (Fig. 4 A), the BN at a later time (Fig. 4 B) (MCA = 0.82, 
AUC = 0.81) retains most of the BN structure. However, the BN in Fig. 4 B includes an 
indirect influence between age and CDR through CSF, GM, and PiB-PET, instead of direct 
influencing CDR as it does at BL. Further, CDR is now directly influenced by ApoE even 
stronger than by CSF. This indicates ApoE may become an important biomarker for AD 
severity over time. MMSE maintains a strongly direct influence from CDR. The significant 
change from the BN at BL is the probabilistic dependencies between logical memory recall 
assessments and CDR, i.e., LMDR would become more important than LMIR.  
To provide further support to the dynamic changes of BNs constructed using the Group 1 
data (Figs. 4 A and B), we conducted the process of BN learning for Group 2 subjects, in 
which the same participants were assessed at both BL and ‘Later time’ (see Supplementary 
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Table S2). Since the BNs models were constructed using the same set of subjects at BL and 
‘Later time’, only time-evolved features were incorporated into the models. Therefore, ApoE 
genotype information was not included for BN learning.  
When comparing Group 2 BN models at BL (Fig. 4 C) and at ‘Later time’ (Fig. 4 D), we 
see that age did not directly influence CDR at ‘Later time’ while CSF became directly linked 
to CDR. In addition, CDR was influenced by PiB-PET more strongly than GM and CSF. More 
importantly, psychological/functional assessments showed again much stronger influence on 
CDR than age and imaging features. For both BNs, the direct influences on AD severity are 
GM and PiB-PET, which are in turn directly influenced by age and indirectly influenced by 
age via CSF and/or GM. This may suggest that GM, PiB-PET, and CSF could be important 
biomarkers for older cohorts. Overall, most of the relationships within the BNs constructed for 
Group 2 (Figs. 4 C and D) are consistent with those developed in BNs using the Group 1 
data. The differences arise only from the weaker connections, namely, GM-CSF-PiB-PET. 
The BNs’ MCAs/AUCs (Figs 4 C and D) at BL and ‘Later time’ are 0.74/0.89 and 0.84/0.92 
respectively. The sensitivity and specificity for each AD severity category is listed in 





Fig. 4. Bayesian networks based on the complete data at different times. (A) Group 1 data at BL 
(197 participants). (B) Group 1 data, assessments conducted at least once during the M18-54 time 
interval (130 participants). (C) Group 2 longitudinal data at BL (133 participants) including time-
evolved features. (D) Group 2 longitudinal data, assessments conducted at least once during the M18-
54 time interval including time-evolved features. The thickness of arrows represents the strength of the 
probabilistic influences between variables. As the Group 2 set uses longitudinal data focuses, the 
ApoE feature was disregarded due to its unchanging nature.  
Bayesian network identified predisposing indicators and biomarkers for 
classification of AD severity 
We now make use of the key predisposing factors and biomarkers and their relations 
identified by the BNs for classification of AD severity. In order to use a larger volume of data, 
we considered all available complete data samples regardless of time point. Supplementary 
Table S2 (bottom panel) lists data distribution across four AD severity categories (i.e. normal 
controls, very mild, mild, and moderate AD), for different combinations of predisposing 
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factors and biomarkers. For example, we considered a total of 1480 subjects with recorded 
age and CDR metric; this number was reduced to 1454 records when ApoE was included in 
the construction of BNs.  
Fig. 5 shows the AUC values calculated for BNs constructed based on different 
combinations of predisposing factors/biomarkers without ApoE (circled markers) and with 
ApoE (squared markers). The BN models using individual markers, i.e. CSF, GM, PiB-PET, 
and age, provide relatively lower AUC in identifying AD severity, compared to their 
combinations. Only one BN model based on the combination of AD markers, specifically Age 
and PiB-PET, achieved lower AUC than BNs constructed using individual features.  
The BN model incorporating all imaging biomarkers (i.e., GM+CSF+PiB-PET) was found 
to have the highest AUC of 0.82 while the BN model constructed with biomarkers and age 
(i.e., age+GM+CSF+PiB-PET) reported AUC of 0.81. These results show that using 
neuroimaging markers can provide sufficiently high detection of AD severity, despite the 
coarseness (total volume or active voxels) in the brain imaging data.  
The incorporation of ApoE feature into the construction of BN models generally improved 
the model performance with an exception of models including both GM or PiB-PET and ApoE. 
The combination of imaging markers and ApoE (i.e. GM+CSF+PiB-PET+ApoE) used for BN 
learning showed the highest AUC of 0.82, followed by the combination of age, imaging 







Fig. 5. Classification accuracy (AUC) of individual predisposing indicators and biomarkers and 
their combinations with respect to CDR. Circled markers: BN models constructed using individual 
as well as combinations of predisposing factors/biomarkers without ApoE. Squared markers: BN 
models constructed using individual as well as combinations of predisposing factors/biomarkers with 
ApoE. The incorporation of ApoE into the BN structure generally improved the model performance. 
Finally, we constructed BN models for which the measure of AD severity was able to be 
directly or indirectly influenced by predisposing factors (i.e. age, GM, CSF, PiB-PET, ApoE) 
as well as the output of psychological/functional assessments. We specifically tested the 
combination of all predisposing factors with individual as well as different configurations of 
cognitive/functional tests (Table 1). We observed that BN models incorporating 
cognitive/functional assessments consistently achieved higher AUC than models based 
solely on predisposing factors. The best model performance was achieved for a set of age, 
ApoE, neuroimaging markers and all 3 functional/cognitive assessments as well as for a 
combination of neuro-markers, age, ApoE, MMSE, and LMDR. In both cases, we reported 
AUC of 0.91 and MCA of 0.80, 95%CI [0.67, 0.89]. 
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Table 1. The AUC and MCA performance of the BN models constructed based on the 
combination of all predisposing factors with cognitive/functional assessments. 
Features AUC MCA 
All predisposing factors 
(Age+GM+CSF+PiB_PET+ApoE4) 0.81 0.72, 95%CI [0.59,0.83] 
All predisposing factors + MMSE 0.86 0.76, 95%CI [0.63,0.86] 
All predisposing factors + LMIR 0.85 0.73, 95%CI [0.60,0.84] 
All predisposing factors + LMDR 0.83 0.69, 95%CI [0.54,0.79] 
All predisposing factors + MMSE + LMIR 0.89 0.81, 95%CI [0.69,0.90] 
All predisposing factors + MMSE + LMDR 0.91 0.80, 95%CI [0.67,0.89] 
All predisposing factors + LMIR + LMDR 0.87 0.75, 95%CI [0.62,0.85] 




This study has successfully applied a hybrid computational approach, which includes BN 
based data modelling, to holistically and efficiently identify multiple important factors, the 
strength of their probabilistic influences and their changes in relation to AD severity (based 
on CDR). This was performed on the heterogeneous 4.5 years AIBL data, which consists of 
rapidly and easily acquired coarse-grained data of various predisposing factors, biomarkers, 
and psychological/functional assessment scores.  
The BNs showed that age, MRI-based GM and CSF, and PiB-PET can directly influence 
AD severity. These 4 direct indicators, when combined, can substantially enhance the correct 
classification of AD severity categories in comparison to individual factors (AUC of ~0.83), 
despite the data being rather coarse-grained (e.g. total brain imaging volume or active voxel). 
Combining with an additional important (indirect) biomarker, ApoE, can increase the overall 
classification accuracy by about 3%. In fact, by adding the appropriate cognitive/functional 
assessment features, we could substantially improve the model. Hence BNs across different 
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time points can be used as a quick and sufficiently accurate identification method of 
important markers of AD severity. Further, all the BNs consistently showed that 
psychological/functional assessments were strongly influenced by AD severity. Hence, our 
model supports the use of these assessments as an important component of the clinical 
diagnostic process.  
Our results are consistent with many studies on AD, including those based on the AIBL 
data. For instance, our BN identified the important role of CSF volume as a biomarker for 
detecting and predicting MCI and AD, similar to 32. Within the AIBL study/data, ApoE ε4 
allele has also been shown to be a biomarker for predicting cognitive decline over 18 
months33,34. However, it should be emphasized that our work did not subjectively pre-select 
the data types and perform limited correlation evaluation. The computational approach 
objectively integrates and evaluates a large portion of the data, before identifying the 
important factors through probabilistic dependencies using BNs. The reduced number of 
identified factors can in turn suggest a smaller, but more efficient, number of tests for 
identifying or predicting very mild or mild AD.  
To avoid subjective clinical classification and diagnosing of AD, we have used clinical 
dementia rating (CDR, which assesses 3 domains of cognition and 3 domains of function) as 
a more objective assessment for AD severity, namely categorizing severity into 5 categories: 
normal control, very mild, mild, moderate, and severe with CDR values of 0, 0.5, 1, 2, and 3, 
respectively 24. A recent work 26 has also used CDR instead of clinical diagnosis as a 
measure of AD severity. However the study scaled CDR into 3 categories: normal control, 
mild, and severe AD with CDR values of 0, 0.5, and others, and hence has a smaller range 
than ours while not strictly adhering to the CDR definition. Further, our work here justified 
CDR as an index of AD severity based on its high correlation with clinical diagnosis. 
With regards to computational approaches, a BN model for MCI and AD has previously 
been proposed35. However, the work demonstrated that manually constructed BNs are 
simpler and more readable for physicians than those fully automatically learned from data. In 
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our work, we provided a semi-automated modelling approach, in which prior knowledge was 
modelled manually according to domain experts and the BNs were constructed automatically 
using an appropriate learning algorithm (see Fig. 1). This resulted in a more informative BN 
that not only revealed probabilistic relations of various factors with AD severity, but also 
among themselves. Other studies using BN analyses on AD were limited to the use of 
biomarkers 10 or non-imaging data 38. In comparison, our work explored a wider variety of 
data. A more recent study has used a structural equation (latent variable) modelling 
approach to identify dependencies linking brain pathology to a wide range of cognitive 
assessments37,38. However, it is not clear how the probabilistic relationships among the 
heterogeneous data types would likely be. The most distinctive parts of our BN modelling 
work were the inclusion of data types across very different levels, and the discovery of the 
changes in probabilistic dependencies as the cohort age or convert to very mild or 
mild/moderate AD.  
Our present study can be extended in several ways. First, our modelling approach would 
need to be extended to handle data with missing values for larger sample size. Second, 
instead of using the convenient total MRI (GM, CSF, WM) volume, the MRI data can be 
segmented into vulnerable regions to be re-investigated. As the data size will be larger, other 
brain imaging modalities, such as FDG-PET, functional MRI, diffusion tensor imaging (DTI) 
and electroencephalography/magnetoencephalography (EEG/MEG), can also be jointly 
investigated. Third, it would be interesting to investigate larger datasets and with additional 
types of data, especially for conversion samples, e.g., the ADNI dataset. 
In conclusion, we have proposed an efficient hybrid computational approach to identify 
key features within heterogeneous coarse-grained data with respect to Alzheimer’s disease 
severity. The probabilistic relationships among the identified data features can be obtained 
using Bayesian network modelling, with multiple Bayesian networks used to model the 
relationships at different time. These key data features and their relationships can then be 




Data description and distribution 
Data was collected by the AIBL study group. AIBL study methodology has been reported 
previously 21. Informed consent was obtained from all subjects. The usage of the AIBL data 
and our submission of the study have been approved by the AIBL Management Committee. 
Within the AIBL non-imaging dataset, there were a total of 861 participants at BL. However, 
only 262, 222, and 142 participants followed up the study after M18, M36, and M54, 
respectively. The data contained demographics, medical history, ApoE genotype, 
psychological/functional assessments, blood analyses, and clinical diagnoses. The brain 
imaging dataset consisted of structural MRI and PET data. We split the MRI data into 3 
complementary features: grey matter (GM), white matter (WM), and cerebrospinal fluid (CSF) 
volumes, as they can be quickly obtained in comparison to segmented vulnerable regions. A 
total of 613 participants at BL had MRI scan, while only 188, 143, and 112 participants 
followed up the scan after M18, M36, and M54, respectively. The PET data is categorised 
into PiB- and FDG-PET data. Within the PiB-PET data, feature active voxels, was collected 
from 207, 177, 137, and 93 participants at BL, M18, M36, and M54, respectively. As the 
number of samples with complete FDG-PET data is very few, we exclude FDG-PET in this 
study. A detailed data description we considered is listed in Supplementary Table S1, with a 
total of 35 features involved.  
Classification of MCI and AD within the cohort were made according to established, 
internationally recognized criteria after thorough review by a multi-disciplinary group of 
academic clinicians experienced in the assessment, diagnosis and management of late-life 
cognitive disorders, particularly MCI and AD 21. We ignored a very small number of cases 
with unknown diagnosis and frontotemporal dementia (FTD). Data distribution across 
diagnostic categories over time is listed in Supplementary Table S4.  
Feature selection and data balancing 
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The feature selection process with 10-fold cross validation was applied exclusively to the 
model development set after setting aside a 10% (independent test set) of the complete data 
(see Fig. 1). Three entropy-based feature selection algorithms were used to select the most 
significant features with respect to clinical dementia rating (CDR). The algorithms are 
information gain (IG), information gain ratio (IGR), and symmetrical uncertainty (SU)39, which 
are defined respectively by 
 𝐼𝐺 = 𝐻 𝐶𝑙𝑎𝑠𝑠 + 𝐻 𝐴𝑡𝑡𝑖𝑏𝑢𝑡𝑒 − 𝐻(𝐶𝑙𝑎𝑠𝑠,𝐴𝑡𝑡𝑟𝑖𝑏𝑢𝑡𝑒) (1) 
 
 𝐼𝐺𝑅 = 𝐻 𝐶𝑙𝑎𝑠𝑠 + 𝐻 𝐴𝑡𝑡𝑖𝑏𝑢𝑡𝑒 − 𝐻(𝐶𝑙𝑎𝑠𝑠,𝐴𝑡𝑡𝑟𝑖𝑏𝑢𝑡𝑒)𝐻 𝐴𝑡𝑡𝑖𝑏𝑢𝑡𝑒  (2) 
 
 𝑆𝑈 = 2𝐻 𝐶𝑙𝑎𝑠𝑠 + 𝐻 𝐴𝑡𝑡𝑖𝑏𝑢𝑡𝑒 − 𝐻(𝐶𝑙𝑎𝑠𝑠,𝐴𝑡𝑡𝑟𝑖𝑏𝑢𝑡𝑒)𝐻 𝐴𝑡𝑡𝑖𝑏𝑢𝑡𝑒 + 𝐻 𝐶𝑙𝑎𝑠𝑠  (3) 
 
where H is Shannon’s Entropy defined by 𝐻 𝑋 = − 𝑃(𝑋!) log! 𝑃(𝑋!)!!!! , with P as the 
probability function40. These were used to find weights of discrete attributes basing on their 
correlation with the target classes. The advantage of the entropy filter is that it makes no 
assumptions about the nature of the data and no disturbances occurring in dynamic 
environments. The technique demonstrated its effectiveness in a range of applications e.g. in 
gene selection for cancer classification41.  
It has been shown that the class imbalance in a data set introduces a bias in the 
performance of predictive models due to their preference towards the majority class42. We 
therefore balanced the unbalanced disease classes in the model development set by 
resampling the original data and creating synthetic instances using the Synthetic Minority 




The class-attribute interdependence maximization (CAIM) algorithm 30 was applied to 
discretize data features with respect to CDR categories. The CAIM criterion measures the 
dependency between the class variable and the discretization variable for attribute, and is 
defined as:  
 𝐶𝐴𝐼𝑀 = 𝑚𝑎𝑥!!𝑀!!!!!!𝑛  (4) 
 
for 𝑟 = 1, 2,… , 𝑛, in which 𝑚𝑎𝑥! is the maximum value within the rth column of the quanta 
matrix (also called a contingency table 30). 𝑀!! is the total number of continuous values of 
attribute that are within the interval.  
Bayesian network modelling 
Bayesian network (BN) was implemented to provide a representation of probabilistic 
dependencies within the heterogenous AD data using directed acyclic graphs. The nodes in 
the BN corresponded to the domain variables and the arcs reflected the probabilistic 
dependencies between associated variables44. Given a set of n variables, 𝑋 = 𝑋!,𝑋!,⋯ ,𝑋! , 
a BN represents a joint probability distribution on 𝑋, 𝑃 𝑋 , defined as  
 𝑃 𝑋 = 𝑃 𝑋! 𝑝𝑎 𝑋!!!∈! , 𝑖 = 1, 2,⋯ , 𝑛 (5) 
 
where 𝑝𝑎 𝑋!  is the set of parents of 𝑋!.  
In order to construct BN structures that reflect probabilistic dependencies in the real data, 
we applied a combination of prior knowledge and data-oriented modelling. We first used 
expert knowledge, including current diagnostic criteria and input from physicians, to select 
relevant AD indicators/markers and then, identified causal and forbidden relationships among 
variables as structural constraints for BN learning. This procedure allowed us to search for 
optimal network structures over a restricted topological space and hence, significantly 
improve computational efficiency.  Note that the constraints were not exhaustive i.e. there 
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were multiple BNs that adhered to a given set of constraints. Accordingly, predisposing 
indicators/biomarkers were presumed to influence directly/indirectly the measure of AD 
severity, which in turn could affect the output of psychological/functional assessments. 
Neuroimaging factors could influence each other, as well as psychological/functional 
assessments. Once relevant constraints were identified, a score-based algorithm was 
implemented for learning the structures of a BN40. The Hill Climbing (HC) score-based 
learning technique was used to identify high-scoring network structures by evaluating local 
changes to a potential network solution and selecting the one that maximized the score 
function45. The following scoring functions were tested: K2 score46, Bayesian Dirichlet 
equivalent (BDE) score47, modified Bayesian Dirichlet equivalent (MBDE) score47, and 
Bayesian Information Criterion (BIC) metric48.  
In order to evaluate the capability of various fitting functions of BNs and compare 
performance of different BN structures, we applied the 10-fold cross validation (CV) 
procedure49. Given a model development set (see Fig. 1), we randomly partitioned the data 
into k = 10 subsets. Each subset (validation set) was used in turn to validate the model fitted 
on the remaining k - 1 subsets (training set). The log-likelihood loss of the validation set for 
each BN fitted from the training set was computed. Loss estimates of each k subset were 
then combined to determine an overall loss and to identify the optimal scoring criterion. 
The generalizability of trained BN models was evaluated on an independent test set 
partitioned from the original data (10% of the complete dataset). Given a smaller set of 
longitudinal data, we used 30% of the original data for the unseen test set to obtain 
more reliable estimation on the testing accuracy of BN models. The criteria retained for 
comparison of BN models were: the area under the curve of the receiving operator 
characteristics curve (AUC), multi-class classification accuracy (MAC), sensitivity and 
specificity, all reported on the independent test set50. 
Hardware and software 
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All computations, including data pre-processing, BN construction and validation, and 
visualisation, were performed using the R statistical software, version 1.0.136 47 (R 
Foundation for Statistical Computing, Vienna, Austria)51. 
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